Drug
TY-9591
TY-9591 is a pharmaceutical drug with 3 clinical trials. Currently 2 active trials ongoing. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
2(67%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_1
1
33%
Ph phase_3
1
33%
Ph phase_2
1
33%
Phase Distribution
1
Early Stage
1
Mid Stage
1
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
1(33.3%)
Phase 3Large-scale testing
1(33.3%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
3
all time
Status Distribution
Active(2)
Completed(1)
Detailed Status
Recruiting2
Completed1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
2
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 11 (33.3%)
Phase 21 (33.3%)
Phase 31 (33.3%)
Trials by Status
completed133%
recruiting267%
Recent Activity
2 active trials
Showing 3 of 3
completedphase_1
[14 C] Study on Mass Balance of TY-9591 in Healthy Chinese Subjects
NCT05871905
recruitingphase_2
TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases
NCT05948813
recruitingphase_3
Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)
NCT05382728
Clinical Trials (3)
Showing 3 of 3 trials
NCT05871905Phase 1
[14 C] Study on Mass Balance of TY-9591 in Healthy Chinese Subjects
NCT05948813Phase 2
TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases
NCT05382728Phase 3
Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3